Nakai Lab

#AAV Lab in the MMG Department @OHSUSOM researching recombinant AAV biology and developing novel AAV vector-medicated #genetherapies to treat disease.

[Nakai Lab @Nakai_Lab]

Excited to share Dr. Ranjan Das' presentation at #ASGCT2026! Our novel AAV epsilon T1 capsid shows enhanced #podocyte transduction, advancing #GeneTherapy for #AlportSyndrome and kidney diseases. A promising step for patients.

#KidneyResearch #AAV #Biotech

[Nakai Lab @Nakai_Lab]

Dr. Nakai will present NeoSakura BTX at the #Science2Startup Symposium (Cambridge, May 13)-an #OHSU startup advancing gene therapy for kidney diseases. Another exciting time ahead! #GeneTherapy #KidneyDisease
https://t.co/WQl7CzqF0S

[Nakai Lab @Nakai_Lab]

Exciting week for #GeneTherapy community! The Nakai lab has 3 oral presentations at #ASGCT2026 (Abs #6, 79, and 170) on a novel AAV clade that unlocks attractive new phenotypes (NAb evasion, podocytes, beta cells, and neurons). Please join Anusha and Ranjan's talks (May 12&13) !

[Nakai Lab @Nakai_Lab]

We have some exciting oral talks at ASGCT this year. Stay tuned for more information.

[Nakai Lab @Nakai_Lab]

Dr. Kei Adachi recently rejoined to our lab after three years of experience in drug discovery research and alliance work in the research department of a pharmaceutical company in Japan.

[Nakai Lab @Nakai_Lab]

New publication alert! 📢The Nakai Lab’s latest work is now live in JoVE. We’re sharing our technique for high-efficiency gene delivery to the mouse kidney using slow retrograde renal pelvis injection. 🐁💉
https://t.co/VebDasS0FO

#AAV #genetherapy #kidney #innovation #research

[Nakai Lab @Nakai_Lab]

Uncertainty is constant in science but progress shouldn’t be. At Nakai Lab, we stay focused, pushing gene therapy forward with resilience and innovation. Excited by the remarkable strides we’ve made and what’s ahead. Stay tuned for upcoming presentations in the coming months.

[Nakai Lab @Nakai_Lab]

Join us at @ASGCT2025 to our oral presentation on AAV gene therapy in non-human primates.🧬

🎤 Dr. Ranjan Das, PhD
📅 May 16, 2025 - 02:15 PM
📍Room 288-290, Convention Center
#ASGCT2025 #GeneTherapy #AAV #kidney

[Nakai Lab @Nakai_Lab]

Congrats to our former #OHSU colleague, Holger, and his team at UCSF, on their new Nature Biotech paper https://t.co/dJwx1D3a6f. Using normothermic machine perfusion of human livers, they provide key insights for clinical #AAV #Liver #GeneTherapy.

[Nakai Lab @Nakai_Lab]

Our work 👉https://t.co/E4jnnsO1er

[Nakai Lab @Nakai_Lab]

The latest Nephrology Digest in the #KidneyInternational journal concisely highlights key advancements in #AAV -based kidney #GeneTherapy - a challenging but promising approach to treating #KidneyDisease. We are honored to see our work cited! https://t.co/izfcsukWTG

[Nakai Lab @Nakai_Lab]

Excited to announce the publication of our new article in Nature Communications! 🎉 We’ve explored gene therapy in different kidney cells using adeno-associated virus. Check it out here 👉https://t.co/9ERnLQSLrW
#AAV #GeneTherapy #kidney #research #Innovation

[Nakai Lab @Nakai_Lab]

Proud of the collaborative efforts of our entire team! Our research on gene therapy for kidney diseases is now featured in OHSU News. Read more: https://t.co/r5aI8KnW6T

[Nakai Lab @Nakai_Lab]

Revolutionizing gene therapy for kidney diseases! Our latest research explores AAV capsids & delivery routes to overcome major challenges including AAV-attacking antibodies. Learn more from our paper published in Nature Communications: https://t.co/2Y889ssn8C

[Nakai Lab @Nakai_Lab]

#GeneTherapy, #AAV, #KidneyDisease, #ChronicKidneyDisease

[Nakai Lab @Nakai_Lab]

Congratulations to my former colleague, Soo-Kyung Lee, PhD, for being featured in The Scientist for their exceptional work on developing gene therapy to treat FOXG1 brain disorder!#GeneTherapy #Neuroscience
https://t.co/KB7TLxgfRu

[Nakai Lab @Nakai_Lab]

Dr.Nakai shares his opinion on plasmid errors and experimental reproducibility. https://t.co/MW8YL8ecsU

[Nakai Lab @Nakai_Lab]

Thank you to everyone who attended Prof. Hiroyuki Nakai’s talk on AAV Vector-Mediated Gene Therapy for Alport Syndrome! We appreciate your interest and engagement. Follow us to stay updated on our latest advancements and exciting research in kidney health!

[Nakai Lab @Nakai_Lab]

Akari Ohashi, a 3rd-year medical student from Niigata University, has completed her training with us and returned to Japan. Thank you for your dedication to AAV research, Akari! Wishing you success in all your future endeavors!

[Nakai Lab @Nakai_Lab]

Join us at @ASN to our oral presentation on a novel AAV gene therapy approach for treating Alport Syndrome.🧬💡

🎤 Dr. Hiroyuki Nakai, MD, PhD
📅 Oct 26, 2024 & 05:40 PM PDT - 05:50 PM PDT
📍Room 1, Convention Center
#ASNKidney #AlportSyndrome #GeneTherapy #AAV